QualityDipStocks / Health Care · Biotech
Kymera Therapeutics KYMR
Outside our quality screen, so we don’t track its dips. It’s at its 52-week high.
Outside our quality screen. No fair value estimate for now: its free cash flow is negative.
Worth knowing
- Revenue up 134% in a year, top 1% of the 1820 we measure
From the data on this page, as of the last close. How we pick these
- Fair value est.
- n/a
- Market Value
- forming
- Off 52-wk high
- at the high
- Risk vs market
- Below marketbeta 0.75
1 bullish · 5 bearish See why
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
No estimate for KYMR: negative free cash flow. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much KYMR moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Moves a bit less than the market, but its own price swings are 4.9× the S&P 500’s (it moves on its own news).
- Beta vs S&P 500
- 0.75
- Volatility
- 62% vs 13% SPY
- Correlation SPY
- 0.15
- Correlation QQQ
- 0.15
How it ranks
Where KYMR stands vs every one of the 1,996 stocks we cover that has the number. Longer bar = better.
Top quarter on 1 of 3 measures
- Free cash flow yield−2.7% · free cash flow vs market capLowest 11%of 1,391
- Dividends + buybacks yield0% · cash paid out or used to retire shares, vs market capLowest 1%of 1,836
- Revenue growth, last 12 months+134% · vs the 12 months beforeTop 1%of 1,814
From SEC filings and our fair value estimate model. A ranking, not advice.
Valuation details
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 1 of 5
GrowthSales grew 134% to $102M over the last 12 months vs the 12 months before (SEC filings).
Top bearish points 5 of 5
ValuationFree cash flow is negative (−$289M over the last 12 months), so there’s no cash-flow value under the price.
ProfitabilityOperating margin narrowed to −138.0% in FY2021 from 542.4% in FY2023 (SEC filings).
ProfitabilityLost $349M over the last 12 months (net income, SEC filings).
Cash returnsShare count up 14.7% in a year: existing holders are being diluted.
QualityDoesn’t pass our quality screen: no positive free cash flow; ROE under 12% and ROIC under 10%; no sales-growth data.
All fundamentals
FCF yield -2.7% · ROE -27% · Sales +134%
Valuation
- P/E
- n/aloss over the last 12 months
- Price / FCF
- n/anegative free cash flow
- FCF yield
- −2.7%
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- 106.62×
- Price / book
- 6.75×
- Market cap
- $10.9Blisted
- Enterprise value
- n/anot reported in its SEC filings
Growth
- Revenue, 12 months
- $102M
- Sales growth, 12 months
- +133.8%vs the 12 months before
- Sales growth, 3 yrs
- −5.7%/yrfrom FY2022
- Diluted EPS, 12 months
- −$3.64
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- −$349M
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- 0.0%
- Operating margin
- n/an/m
- Net margin
- n/an/m
- FCF margin
- n/an/m: revenue near zero
- Return on equity
- −27%
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $971M
- Total debt
- n/anot reported in its SEC filings
- Net cash
- n/acash or debt not tagged in SEC data
- Debt / equity
- n/adebt or equity not tagged in SEC data
- Interest coverage
- n/ainterest expense not tagged in SEC data
Cash flow & returns
- Free cash flow, 12 months
- −$289M
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- +14.7%diluted shares vs a year ago
- Stock-based comp
- $68M
Trailing 12 months to Sep 30, 2026; balance sheet at Sep 30, 2026. From Kymera Therapeutics’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $-0.3B
- Free cash flow, 12 months−$0.3B
- Free-cash-flow yield-2.7%
- Gross margin0%
- Operating marginn/m
- Return on invested capital−44%
- Return on equity−27%
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $127.51
- 52-wk lowlowest close, 1 year$58.66−54.0%
- PriceMon Nov 2 close$127.51you are here
- 52-wk highhighest close, 1 year$127.51at the price
Momentum & 52-week range
RSI 70 · 5 days +11.0%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
KYMR is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on Kymera Therapeutics in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 1:01 PM ET.
Compare with peers
Closest in size in Biotech
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.